A7231

AZ11645373

≥98% (HPLC), solid

• Synonym(e): 3-[1-[[(3′-nitro[1,1′-biphenyl]-4-yl)oxy]methyl]-3-(4-pyridinyl)propyl]-2,4-thiazolidinedione
• Empirische Formel (Hill-System): C₂₄H₂₁N₃O₅S
• CAS-Nummer: 227088-94-0
• Molekulargewicht: 463.51
• UNSPSC Code: 12352200
• NACRES: NA.77
• Assay: ≥98% (HPLC)
• Form: solid

Eigenschaften

• InChI: 1S/C24H21N3O5S/c28-23-16-33-24(29)26(23)21(7-4-17-10-12-25-13-11-17)15-32-22-8-5-18(6-9-22)19-2-1-3-20(14-19)27(30)31/h1-3,5-6,8-14,21H,4,7,15-16H2
• InChI key: VQEHBLGYANQWEA-UHFFFAOYSA-N
• assay: ≥98% (HPLC)
• form: solid
• color: tan
• solubility: DMSO: ≥10 mg/mL
• originator: AstraZeneca
• storage temp.: 2-8°C

Beschreibung

Application

AZ11645373 is a selective and potent human P2X₇ purinoceptor antagonist. AZ11645373 has been used in the rhesus macaque monkey to elucidate the mechanisms and pharmacological interventions of P2X₇ receptor-related diseases.

Biochem/physiol Actions

AZ11645373 is a selective and potent human P2X₇ purinoceptor antagonist. K_B values range from 5-20 nM for human P2X₇ receptor inhibition. It is 500-fold less effective ats an inhibitor of rat P2X7 receptor responses.

Selective and potent human P2X₇ purinoceptor antagonist

Features and Benefits

This compound is featured on the P2 Receptors: P2X Ion Channel Family page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sicherheitshinweise

• pictograms: GHS05,GHS07
• signalword: Danger
• hcodes: H315,H318,H335
• pcodes: P280 - P302 + P352 - P305 + P351 + P338 + P310
• Hazard Classifications: Eye Dam. 1 - Skin Irrit. 2 - STOT SE 3
• target_organs: Respiratory system
• Lagerklasse: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: dust mask type N95 (US), Eyeshields, Gloves